# GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

> **NCT03161379** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 31 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Nivolumab
- **DRUG:** GVAX Pancreas Vaccine
- **RADIATION:** Stereotactic Body Radiation (SBRT)

## Key facts

- **NCT ID:** NCT03161379
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-02
- **Primary completion:** 2024-02-20
- **Final completion:** 2024-02-28
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03161379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03161379, "GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03161379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*